-
公开(公告)号：US08592462B2
公开(公告)日：2013-11-26
申请号：US13312746
申请日：2011-12-06
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4412 , A61K31/4418 , G01N33/576 , G01N33/6893 , G01N2800/52 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
-
2.发明授权公开(公告)号：US07566729B1
公开(公告)日：2009-07-28
申请号：US12428393
申请日：2009-04-22
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
IPC: A61K31/445
CPC classification number: A61K31/445 , Y02A50/401 , Y02A50/411
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage.
Abstract translation: 提供了用于向依托吡非尼酮给药反应呈现出肝功能异常生物标志物的患者施用吡非尼酮的方法。 所述方法包括以低于全部目标剂量的剂量给予患者吡非尼酮一段时间，然后以完全目标剂量施用于患者吡非尼酮。
-
公开(公告)号：US08084475B2
公开(公告)日：2011-12-27
申请号：US12684543
申请日：2010-01-08
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4418 , A61K31/4412 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Abstract translation: 本发明涉及避免与吡非尼酮和CYP诱导剂（例如吸烟）的不良药物相互作用的方法。
-
公开(公告)号：US08648098B2
公开(公告)日：2014-02-11
申请号：US13326971
申请日：2011-12-15
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4418 , A61K31/4412 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Abstract translation: 本发明涉及避免与吡非尼酮和CYP诱导剂（例如吸烟）的不良药物相互作用的方法。
-
公开(公告)号：US07635707B1
公开(公告)日：2009-12-22
申请号：US12553292
申请日：2009-09-03
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
IPC: A61K31/445
CPC classification number: A61K31/4412 , A61K31/4418 , G01N33/576 , G01N33/6893 , G01N2800/52 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Abstract translation: 提供了用于向依托吡非尼酮给药反应呈现出肝功能异常生物标志物的患者施用吡非尼酮的方法。 所述方法包括以低于全部目标剂量的剂量给予患者吡非尼酮一段时间，然后以完全目标剂量施用于患者吡非尼酮。 所述方法还包括以完全目标剂量施用吡非尼酮，而不减少并施用永久减少剂量的吡非尼酮。
-
Patent Agency Ranking
公开(公告)号：US08609701B2
公开(公告)日：2013-12-17
申请号：US13128569
申请日：2009-11-09
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4412 , A61K31/4418 , G01N33/576 , G01N33/6893 , G01N2800/52 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
-
公开(公告)号：US08318780B2
公开(公告)日：2012-11-27
申请号：US13224589
申请日：2011-09-02
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4418 , A61K31/135 , A61K31/15 , A61K31/44 , A61K36/752 , A61K45/06 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Abstract translation: 本发明涉及避免与氟伏沙明和吡非尼酮或CYP酶的其它中等至强抑制剂的不良药物相互作用的方法。
-
公开(公告)号：US08013002B2
公开(公告)日：2011-09-06
申请号：US13049894
申请日：2011-03-16
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4418 , A61K31/135 , A61K31/15 , A61K31/44 , A61K36/752 , A61K45/06 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
-
公开(公告)号：US07910610B1
公开(公告)日：2011-03-22
申请号：US12901245
申请日：2010-10-08
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4418 , A61K31/135 , A61K31/15 , A61K31/44 , A61K36/752 , A61K45/06 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Abstract translation: 本发明涉及避免与氟伏沙明和吡非尼酮或CYP酶的其它中等至强抑制剂的不良药物相互作用的方法。
-
公开(公告)号：US07816383B1
公开(公告)日：2010-10-19
申请号：US12684879
申请日：2010-01-08
Applicant: Williamson Ziegler Bradford , Javier Szwarcberg
Inventor： Williamson Ziegler Bradford , Javier Szwarcberg
CPC classification number: A61K31/4418 , A61K31/135 , A61K31/15 , A61K31/44 , A61K36/752 , A61K45/06 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/475
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
Abstract translation: 本发明涉及避免与氟伏沙明和吡非尼酮或CYP酶的其它中等至强抑制剂的不良药物相互作用的方法。
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.022 seconds)
